Combining PARP inhibitors with tumor-infiltrating lymphocytes — harvested from tumors and cultured outside the body — may offer a viable therapeutic strategy for triple-negative breast cancer. This evidence concerns the gene PARP1 and triple-negative breast carcinoma.